Synthetic strategies for the construction of C3-fluorinated oxindoles

R Singh - Organic & Biomolecular Chemistry, 2023 - pubs.rsc.org
C3-fluorinated oxindoles are important scaffolds known to demonstrate various biological
properties. As bio-isosteres of oxindoles, these compounds have shown tremendous …

New imatinib derivatives with antiproliferative activity against A549 and K562 cancer cells

A Oliveira, S Moura, L Pimentel, J Neto, R Dantas… - Molecules, 2022 - mdpi.com
Tyrosine kinase enzymes are among the primary molecular targets for the treatment of some
human neoplasms, such as those in lung cancer and chronic myeloid leukemia. Mutations in …

Novel α-Aminophosphonates of imatinib Intermediate: Synthesis, anticancer Activity, human Abl tyrosine kinase Inhibition, ADME and toxicity prediction

S Aita, VN Badavath, M Gundluru, M Sudileti… - Bioorganic …, 2021 - Elsevier
An efficient method for the synthesis of a new class of α-aminophosphonates of imatinib
derivative has been developed in one-pot Kabachnik-Fields reaction of N-(5-amino-2-methyl …

Repurposing strategies for Chagas disease therapy: the effect of imatinib and derivatives against Trypanosoma cruzi

MR Simões-Silva, JS De Araújo, RB Peres… - Parasitology, 2019 - cambridge.org
Chagas disease (CD) is a neglected parasitic condition endemic in the Americas caused by
Trypanosoma cruzi. Patients present an acute phase that may or not be symptomatic …

Spirooxadiazoline‐oxindoles derived from imatinib show antimyeloproliferative potential in K562 cells

LD de Azevedo, DI Leite, AP de Oliveira… - Archiv der …, 2024 - Wiley Online Library
Imatinib mesylate was the first representative BCR‐ABL1 tyrosine kinase inhibitor (TKI) class
for the treatment of chronic myeloid leukemia. Despite the revolution promoted by TKIs in the …

(Phenylamino) pyrimidine-1, 2, 3-triazole derivatives as analogs of imatinib: searching for novel compounds against chronic myeloid leukemia

LCF Pimentel, LVB Hoelz, HF Canzian… - Beilstein Journal of …, 2021 - beilstein-journals.org
The enzyme tyrosine kinase BCR-Abl-1 is the main molecular target in the treatment of
chronic myeloid leukemia and can be competitively inhibited by tyrosine kinase inhibitors …

SPHINX-based combination therapy as a potential novel treatment strategy for acute myeloid leukaemia

C Wodi, T Belali, R Morse… - British Journal of …, 2023 - frontierspartnerships.org
Introduction: Dysregulated alternative splicing is a prominent feature of cancer. The
inhibition and knockdown of the SR splice factor kinase SRPK1 reduces tumour growth in …

Hetarylfuroxans: cytotoxic effect and induction of apoptosis in chronic myeloid leukemia K562 cells

SA Pukhov, LA Anikina, AA Larin, LL Fershtat… - Russian Chemical …, 2019 - Springer
Abstract Hetarylfuroxans (4-(2-methylpyridin-5-yloxy)-3-phenylfuroxan (1), bis (1, 2, 4-
oxadiazol-3-yl) furoxan (2), and 4-amino-3-(indenotriazin-3-yl) furoxan (3)) exhibit in vitro …

[HTML][HTML] Hybrids of Imatinib with Quinoline: Synthesis, Antimyeloproliferative Activity Evaluation, and Molecular Docking

C Santos, L Pimentel, H Canzian, A Oliveira, F Junior… - Pharmaceuticals, 2022 - mdpi.com
Imatinib (IMT) is the first-in-class BCR-ABL commercial tyrosine kinase inhibitor (TKI).
However, the resistance and toxicity associated with the use of IMT highlight the importance …

[HTML][HTML] Synthesis, Spectroscopic Identification and Molecular Docking of Certain N-(2-{[2-(1H-Indol-2-ylcarbonyl) hydrazinyl](oxo)acetyl}phenyl)acetamides and N-[2-(2-{[2 …

MS Almutairi, AS Zakaria, RI Al-Wabli, IH Joe… - Molecules, 2018 - mdpi.com
N-(2-{[2-(1 H-Indol-2-ylcarbonyl) hydrazinyl](oxo) acetyl} phenyl) acetamides (5a–h) and N-
[2-(2-{[2-(acetylamino) phenyl](oxo) acetyl} hydrazinyl)-2-oxoethyl]-1 H-indole-2 …